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Tumor growth is associated with a profound alter-
ation in myelopoiesis, leading to recruitment of
immunosuppressive cells known as myeloid-derived
suppressor cells (MDSCs). We showed that among
factors produced by various experimental tumors,
the cytokines GM-CSF, G-CSF, and IL-6 allowed a
rapid generation of MDSCs from precursors present
in mouse and human bonemarrow (BM). BM-MDSCs
induced by GM-CSF+IL-6 possessed the highest
tolerogenic activity, as revealed by the ability to
impair the priming of CD8+ T cells and allow long
term acceptance of pancreatic islet allografts. Cyto-
kines inducing MDSCs acted on a common molec-
ular pathway and the immunoregulatory activity of
both tumor-induced and BM-derived MDSCs was
entirely dependent on the C/EBPb transcription
factor. Adoptive transfer of tumor antigen-specific
CD8+ T lymphocytes resulted in therapy of estab-
lished tumors only in mice lacking C/EBPb in the
myeloid compartment, suggesting that C/EBPb is a
critical regulator of the immunosuppressive environ-
ment created by growing cancers.
INTRODUCTION
Tumors can induce a state of T cell unresponsiveness toward
tumor antigens, i.e., tolerance, which subsequently evolves in
a generalized failure to respond to various antigens, i.e., immune
suppression, when the tumor progresses (Gabrilovich and Na-
garaj, 2009; Marigo et al., 2008). Although several mechanisms
have been proposed to account for the immune abnormalities
in tumor-bearing hosts, an important role is played by the
tumor-induced alteration in myelopoiesis (Sica and Bronte,
2007). Myeloid-derived suppressor cells (MDSCs) have been790 Immunity 32, 790–802, June 25, 2010 ª2010 Elsevier Inc.characterized in mice with cancer as a population of myelomo-
nocytic cells bearing the surface markers CD11b and Gr-1
(Ly6C and/or Ly6G) and able to restrain the function of
antigen-stimulated CD8+ and CD4+ T lymphocytes (Gabrilovich
and Nagaraj, 2009; Marigo et al., 2008). Although it is generally
accepted that MDSCs are elicited by tumor-derived factors
from precursors present in hematopoietic organs such as the
bone marrow (BM) and possibly spleen (at least in mice), key
transcriptional regulators of MDSC biology and function are still
poorly defined.
We previously showed that short term in vivo administration
of mouse granulocyte-macrophage colony-stimulating factor
(GM-CSF) was sufficient to induce a transient increase in
CD11b+Gr-1+ MDSCs and impairment of response of CD8+
T cells to recall antigens (Bronte et al., 1999). Moreover, trans-
fection of a melanoma tumor cell line lacking GM-CSF, with a
retroviral vector encoding the cytokine, was sufficient to
cause tumor-dependent expansion of splenic CD11b+Gr-1+
cells and induce cytotoxic T lymphocyte (CTL) immune
dysfunctions when the engineered melanoma subclones were
inoculated and allowed to grow in mice (Bronte et al., 1999).
More recently, we demonstrated that silencing GM-CSF in a
mammary carcinoma resulted in the reduction of MDSCs and
abrogation of the systemic immunosuppression induced by
this tumor (Dolcetti et al., 2010). Interestingly, GM-CSF drove
the expansion of CD11b+Gr-1int and CD11b+Gr-1lo cell subsets
in the spleen of tumor-bearing mice, and these subsets were
mainly responsible for tumor-induced immune dysfunctions.
Although these and other data (Serafini et al., 2004) have clearly
highlighted the role of GM-CSF in controlling MDSCs in vivo,
our attempts to generate fully competent MDSCs from BM
precursors using GM-CSF were not completely successful.
Moreover, GM-CSF is not the only myelopoiesis-inducing cyto-
kine present in the tumor microenvironment. We thus decided
to investigate the cytokines most present in the tumor microen-
vironment to identify the minimal factor combination required
for in vitro MDSC generation and then pinpoint the transcription
factors regulating the biological properties of myeloid suppres-
sors. This process allowed us to identify C/EBPb as master
Figure 1. Cytokine-Stimulated BM Cells
Express IL-4Ra and Inhibit Antigen-Induced
T Lymphocyte Cytotoxicity
(A) Accumulation of CD11b+Gr-1+ cells and IL-4Ra
expression in BM cells after 4 days of culture in the
presence of different cytokines are showed in
contour and histogram plots, respectively.
Contour and histograms are from one out of nine
independent experiments, whereas mean fluores-
cence intensity (MFI) values are presented as
mean ± SD of nine independent experiments.
*p % 0.05 and **p % 0.01, Student’s t test, all
comparisons between cytokine-treated BM
versus fresh BM.
(B) In vitro suppressive activity of BM-derived
MDSCs when added to a MLPC set up with
HA-specific CD8+ T lymphocytes from CL4 trans-
genic mice stimulated in vitro with HA512-520
peptide. After 5 days, cytotoxic activity was tested
in a 5 hr 51Cr-release assay. BM-derived cells were
added to MLPC at different percentages of the
total number of cells present in the cultures
(12%, 6%, and 3%). Data are expressed as the
ratio between L.U.30 in MDSC-containing cultures
and in control cultures set up in the absence of
MDSCs. Mean ± SD; *p % 0.05 and **p % 0.01;
Student’s t test, all comparisons are among
MDSC containing cultures versus cultures without
MDSCs.
See also Figure S1.
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C/EBPb Controls Tumor-Induced Toleranceregulator of the tolerogenic and immunosuppressive environ-
ment induced by cancer.
RESULTS
Characterization of MDSCs Induced In Vitro by Cytokine
Treatment
Among the various factors we tested for the ability to affect
myelopoiesis, we found that the cytokines IL-6 and granulocyte
colony-stimulating factor (G-CSF), in addition to GM-CSF, were
produced by either cancer cells themselves or tumor-associ-
ated myeloid cells (Figures S1A–S1C). We thus decided to
evaluate whether these cytokines could be used to generate
MDSCs in vitro from bone marrow (BM) precursor cells. GM-
CSF-mediated induction of MDSCs required only 3 to 4 days
of in vivo cytokine administration (Bronte et al., 1999, 2000).
This observation led us to speculate that we might drive
in vitro MDSC differentiation in short term culture of BM cells
in the presence of appropriate stimuli. We thus cultured whole
BM cells for 4 days with GM-CSF, G-CSF, IL-6, or a combination
of these cytokines and monitored the induction of the a chain of
the receptor for IL-4 (IL-4Ra, CD124), which was found to be
a key component for the activation of the MDSC suppressiveImmunity 32, 790–8program (Gallina et al., 2006; Serafini
et al., 2006, 2008). In parallel, we also
assessed whether in vitro cultured BM
cells were able to suppress the lytic
activity of CD8+ T lymphocytes (CL4
cells) expressing a transgenic T cell
receptor (TCR) specific for influenzahemagglutinin (HA). IL-4Ra expression was negligible in
CD11b+Gr-1+ cells freshly isolated from BM, and these cells
did not possess inhibitory activity when added at different
concentrations to HA-peptide stimulated CL4 CTLs (Figures 1A
and 1B). Both IL-6 and G-CSF treatment did not markedly
change surface IL-4Ra amounts on BM cells; moreover, IL-6
had a detrimental effect on cell viability, thereby preventing
any further functional characterization. Despite the increased
IL-4Ra expression following G-CSF treatment, this cytokine
did not induce any appreciable imunosuppressive function in
BM cells. GM-CSF induced a significant increase (p = 0.028
versus untreated BM) of IL-4Ra expression, and BM cells
cultured with this cytokine inhibited CTL activity in a dose-
dependent fashion (Figures 1A and 1B). However, the addition
of either GM-CSF+G-CSF or GM-CSF+IL-6 combinations to
these short term cultures was able to generate cells with
enhanced expression for CD11b and Gr-1 markers, high
IL-4Ra expression (p = 0.0029 and p = 0.0016 versus fresh BM,
respectively), and significant inhibitory activity against antigen-
activated CL4 T lymphocytes even at lower cell percentages
(Figures 1A and 1B). Analogous inhibitory activity was exerted
on alloantigen-stimulated CTL in standard mixed leukocyte
reaction (MLR) cultures (data not shown).02, June 25, 2010 ª2010 Elsevier Inc. 791
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MDSCs was further characterized in BALB/c and C57BL/6
mice (Figures S1D and S1E, respectively) and compared to
CD11b+ cells isolated from either fresh BM or spleen of tumor-
bearing mice. We identified the two major MDSC subsets:
CD11b+Gr-1hiCD62L+F4/80+/ granulocytic and CD11b+Gr-1lo
CD62LF4/80+ monocytic cells, as previously described (Gabri-
lovich and Nagaraj, 2009; Sica and Bronte, 2007; Youn et al.,
2008). BM-MDSCs derived from C57BL/6 mice retained the
ability to inhibit the stimulation of gp100-specific CD8+ T
lymphocytes derived from p-mel-1 transgenic mice (Figure S1F).
CD11b+ cells in the spleens of tumor-free mice did not
comprise MDSC precursors because inhibitory functional prop-
erties could not be induced by exposing these normal CD11b+
splenocytes to the aforementioned cytokines (data not shown),
suggesting that MDSC precursors mainly reside in normal BM.
BM-MDSCs Induce T Cell Antigen Unresponsiveness
In Vivo
To evaluate BM-MDSC tolerogenic activity on antigen-specific
CD8+ T cells in vivo, we used an experimental model in which
naive CL4 T cells (Thy1.1) were transferred to Thy1.2 congeneic
recipients, which were immunized, 2 days later, with DCs pulsed
with class I MHC-restricted HA512-520 peptide. MDSCs from
C26-GM tumor-bearing mice and BM-MDSCs, either pulsed or
not with HA512-520 peptide, were transferred on the same day
of the immunization as well as 5 days later. Draining lymph
node cells were collected 12 days after immunization and stim-
ulated in vitro to enumerate CD8+ T cells producing IFN-g
(Figures S2A and S2B). Both the number of Thy1.1+ cells and
number of IFN-g secreting CD8+ T cells present in draining lymph
nodes were significantly reduced in mice that received MDSCs
derived from either tumor-bearing mice or BM conditioned with
GM-CSF and IL-6, but not with the combination GM-CSF+G-
CSF. Moreover, as previously described (Nagaraj et al., 2007),
in this model, MDSC tolerogenic activity was antigen dependent
because no difference was observed when peptide unpulsed
MDSCs were adoptively transferred (Figure 2A). It thus appears
that, despite the overall phenotypic similarity, GM-CSF+G-CSF
and GM-CSF+IL-6 regimens induced MDSCs with different
in vivo tolerogenic potential. It must be pointed out that in vitro
inhibitory activity of GM-CSF+IL-6-driven MDSCs was indeed
the highest on a per cell basis (Figure 1B), suggesting a greater
immunosuppressive potential. Indeed, a strict correlation
between high in vitro and in vivo immune suppressive activity
was recently demonstrated for tumor-induced MDSCs (Dolcetti
et al., 2010).
To prove further that in vitro generated MDSCs might induce
a persistent tolerance toward self antigens, we established a
model of allotransplantation of pancreatic islets in pharmacolog-
ically-induced diabetic mice. In this model, diabetic mice survive
indefinitely when transplanted with syngeneic islet cells under
the kidney capsule, whereas the allogeneic transplant is rejected
within 3 to 4 weeks (Figure 2B and Figure S2C). Adoptive transfer
of recipient-derived, syngeneic MDSCs (a total of four weekly
injections starting the same day of islet transplant) increased
the percentage of long-term survivors in the group of mice trans-
planted with allogeneic islets in the absence of any immunosup-
pressive drug administration (Figure 2B). In agreement with the792 Immunity 32, 790–802, June 25, 2010 ª2010 Elsevier Inc.enhanced tolerogenic activity shown before, the difference
between the control mice not receiving any BM-MDSCs or
receiving syngeneic BM-MDSCs was significant only in the
case of BM-MDSCs generated with GM-CSF and IL-6 (p <
0.0001, Figure 2B). In this treatment group, about 75% of mice
remained normoglycemic and healthy for the entire observation
period of 200 days, analogously to all the control mice trans-
planted with syngeneic islets.
At rejection, or at given time points following transplantation,
kidneys containing islet allografts were morphologically exam-
ined by histology and immunohistochemistry to assess the state
of the graft, the insulin content, and the phenotypic characteriza-
tion of inflammatory cells (Figure 2C and Figure S2D). Following
syngeneic transplantation, strong insulin staining was present in
all animals at all time points assessed up to 200 days. Untreated
recipients of allografts, euthanized following the rise in glucose
amount, presented insulitis with mild lymphocytic infiltrate
comprising CD4+ and CD8+ T cells and CD49b+ cells with
little to no insulin staining. Following treatment with MDSCs,
the histological outcome varied between full rejection (GM-
CSF+G-CSF-derived MDSCs), similar to that in untreated allo-
grafts, to long-term graft survival, with diffuse insulin staining in
the presence of lymphocytic infiltration (GM-CSF+IL-6-derived
MDSCs). In the latter group, the lymphocytic infiltration
(comprising CD4+, CD8+ T cells, and CD49b+ cells) was usually
confined to the areas surrounding the insulin-positive graft, a
histological pattern not compatible with insulitis (Figure 2C and
Figure S2D).
To confirm the induction of tolerance against alloantigen
present in the islet cells, mice were transplanted with allogeneic
or syngeneic islets and treated with 3 administrations of
GM-CSF+IL-6-derived MDSCs. Three weeks after the islet
transplantation, mice were euthanatized and cells from spleens
or mesenteric lymph nodes were then stimulated in vitro with
disaggregated syngeneic or allogeneic islet cells to stimulate
IFN-g-producing T cells. Mice transplanted with allogeneic insu-
lae and not treated with BM-MDSCsmounted a strong response
against islet alloantigens, whereas recipient mice treated with
BM-MDSCs showed a response comparable to control mice
that did not receive either islet transplant or BM-MDSCs
(Figure 2D). Intracellular staining for IFN-g indicated that the
majority of cells responding to islet alloantigens were CD8+
rather than CD4+ T cells (data not shown). The allotransplant
was necessary to prime in vivo antigen-specific effector T cells
because mice that did not receive any transplant failed to recog-
nize islet alloantigens; moreover, mice transplanted with C57BL/
6 islets and restimulated in vitro did not recognize antigenically
unrelated FVB islet cells (Figure 2D). Finally, administration of
BM-MDSCs did not result in a generalized immune suppression
because recognition of alloantigens on splenocyte target cells
was maintained (Figure S2E).
The number of cells inoculated in vivo in our islet transplanta-
tion experiments was chosen to assure a tolerogenic environ-
ment mimicking that induced by growing tumors, since protocol
optimization was not our primary interest. However, it must be
pointed out that culture of BM cells with cytokine mixtures
allowed us to recover almost the same number of plated cells
(Figure S2F, left panel). Moreover, when we titered down the
numbers of BM-MDSCs necessary to reduce the function of
Figure 2. BM-Derived MDSCs Induce Tolerance upon Adoptive Transfer
(A) Mice were treated as described in Figure S2A. Ten days after immunization, lymph node cells were restimulated with or without the specific HA peptide and
cells labeled with CD8, anti-Thy1.1, and anti-IFN-gmAbs. The number of Thy1.1+ cells/106 CD8+cells and number of IFN-g-releasing cells/106 CD8+ cells were
evaluated by flow cytometry. Mean ± SD, n = 6 mice/group pooled from two independent experiments. *p < 0.05 in comparison with No MDSC group.
(B) Tolerogenic activity of MDSCs was tested in amodel of subcapsular islet transplantation in diabeticmice, as indicated in Figure S2B. Glycemia wasmeasured
three times a week, and the animals were euthanized when glucose concentration was higher than 250 mg/dL on two consecutive measurements (n = 23 for
untreated allotransplant controls; n = 10 for GM-CSF+G-CSF MDSCs; n = 20 for GM-CFS + IL-6 MDSCs; n = 11 for syngeneic transplant controls, 3 independent
experiments; ***p% 0.001 in comparison with untreated allotransplant control).
(C) Immunohistochemical analysis of kidneys containing islet grafts from animals in different treatment groups. Original magnification was 603.
(D) BALB/c recipient mice were transplanted with pancreatic insulae from allogeneic (C57BL/6) mice. Groups of mice transplanted with allogeneic islet cells also
received intravenous adoptive transfer of BM-derived MDSCs generated with GM-CSF+ IL-6. As a control of naive response, untransplanted mice were also
included. After three treatments with MDSCs, mice were euthanized and either splenocytes or mesenteric lymph node cells from individuals mice were restimu-
latedwith digested islets from either BALB/c or C57BL/6mice. After 5 days of stimulation, IFN-g release by T lymphocytes cocultured for 24 hr with disaggregated
stimulator islet cells from BALB/c, FVB, or C57BL/6 mice was assessed by ELISA. Data are mean ± SD of the differences between the same samples stimulated
in vitro with either allogeneic islets or syngeneic islets; n = 3 mice/group, two independent experiments, *p% 0.05, Student’s t test.
See also Figure S2.
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C/EBPb Controls Tumor-Induced Toleranceantigen-specific CD8+ T cells following in vivo adoptive transfer,
we found that 1.2 3 106 cells administered twice were sufficient
(Figure S2G), which is about 1/10 of the cells we transferred to
mice transplanted with allogeneic insulae. We hypothesize that
it is possible to reduce further the numbers of cells to be inocu-
lated in vivo to obtain tolerance because Ly6G-negative cells,which represent about half of total BM-MDSCs, possessed the
highest immunoregulatory properties (Figures S2H and S2I).
These results are in full agreement with the recent definition of
discrete subsets of MDSCs with different suppressive capability
in tumor-bearing mice (Dolcetti et al., 2010). We recently demon-
strated that, in fact, among tumor-induced CD11b+Gr-1+ cells,Immunity 32, 790–802, June 25, 2010 ª2010 Elsevier Inc. 793
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C/EBPb Controls Tumor-Induced ToleranceCD11b+Gr-1int and CD11b+Gr-1lo, but not CD11b+Gr-1hi, cell
populations possessed tolerogenic activity on CD8+ T lympho-
cytes, both in vitro and in vivo (Dolcetti et al., 2010). Interestingly,
the most tolerogenic fraction of BM-MDSCs (Gr-1lo) contained
a population of cells with monocyte morphological features
(Figure S2H) expressing markers of DCs (CD11c and class II
MHC) together with monocytic markers (CD115 and F4/80,
Figure S2J). When transferred in vivo to either tumor-free or
tumor-bearing recipients, BM-derived MDSCs could be de-
tectedmainly in the spleen and theymanifested a clear tendency
to acquire CD11c and MHC class II molecules while preserving
various amounts of F4/80 antigen (Figures S2K and S2L), sug-
gesting that this monocytic like population might be responsible
for part of the in vivo tolerogenic activity.
C/EBPb Is Necessary for the Immunosuppressive
Program in Both Tumor-Induced and BM-Derived
MDSCs
Considering the possible molecular targets of GM-CSF and IL-6
involved in myelopoiesis regulation, we focused our attention on
the C/EBP family of transcription factors. In particular, whereas
C/EBPa is the ‘‘master regulator’’ of the steady-state granulopoi-
esis, C/EBPb controls emergency granulopoiesis induced by
cytokines and infections (Hirai et al., 2006). Although C/EBPb
has never been associated with immune regulation, we asked
whether C/EBPb might play any role in MDSC development
and biological functions.
Three isoforms of C/EBPb with different molecular weights
have been described: liver-inhibitory protein (LIP), liver-acti-
vating protein (LAP), and full-length liver-activating protein
(LAP*) (Qiu et al., 2008). We performed immunoblot analysis on
CD11b+ cells infiltrating four different tumors and detected
various isoforms of C/EBPb, whereas expression of C/EBPb in
CD11b+ splenocytes of the same tumor-bearing mice could be
observed only in mice with C57BL/6 genetic background
(Figure 3A, upper blot). C/EBPb was barely detectable in BM
cells, but the exposure of BM to GM-CSF and IL-6 caused
a time-dependent upregulation of C/EBPb isoforms, with some
differences related to mouse background: in fact, whereas
the three isoforms were all induced in C57BL/6 background
(Figure 3A, lower left blot), LIP and LAP prevailed in BALB/c
(Figure 3A, lower right blot). Interestingly, genome profiling
suggested closer similarities between BM-MDSCs and tumor-
infiltrating CD11b+ cells than between BM-MDSCs and splenic
CD11b+ cells of tumor-bearing hosts (Figures S3A and S3B).
To understand the importance of C/EBPb in vivo, we created
a model of tissue-restricted gene ablation. Cebpb was deleted
in all hematopoietic lineage cells using the deleter strain
B6.Cg-Tg(Tek-Cre)1Ywa (Tie2 transgene abbreviated here as
Tie2cre), as previously reported for other genes (El Kasmi
et al., 2008). We isolated BM cells from wild-type (+/+), hemizy-
gous Cebpbflox/+;Tie2cre (+/) and fully ablated Cebpbflox/flox;-
Tie2cre (/) mice and exposed them to GM-CSF+IL-6
in vitro. Immunoblot analysis of BM-MDSCs confirmed either
the loss or reduction of C/EBPb in cells derived from fully ablated
and hemizygous mice, respectively (Figure 3B, upper panel).
Only complete loss of C/EBPb resulted in full abrogation of
BM-MDSC immunosuppressive activity on antigen-activated
CD8
+
T cells (Figure 3B, lower panel). This was also confirmed794 Immunity 32, 790–802, June 25, 2010 ª2010 Elsevier Inc.in vivo in mice bearing the fibrosarcoma MCA203: Cebpbflox/flox;
Tie2cre (/) mice showed a decrease in CD11b+Gr-1+ cells and
when remaining CD11b+ splenocytes were isolated from the
spleen of these mice, these cells had completely lost their ability
to inhibit in vitro antigen-specific CD8+ T cells (Figure 3C).
The percentage (Figure 3D) and total number (data not shown)
of CD11b+ splenocytes were significantly decreased in MCA203
tumor-bearing Cebpbflox/flox;Tie2cre (/), but not in hemizy-
gous Cebpbflox/+;Tie2cre (+/) mice. Unexpectedly, however,
not all the myelomonocytic cell subsets were equally affected
by lack of C/EBPb. When we analyzed the percentage of the
different subsets of CD11b+Gr-1+ cells, percentages of
CD11bhiGr-1hi and CD11bhiGr-1 cells were decreased in both
C/EBPb-deficient strains, but subsets characterized by low
and intermediate expression of the Gr-1 marker were signifi-
cantly decreased only in fully ablated mice (Figure 3D).
To address the role of C/EBPb in tumor-induced tolerance
in vivo, EG-7 tumor cells expressing the model tumor antigen
ovalbumin (OVA) were inoculated subcutaneously inCebpbflox/+;
Tie2cre (+/) and Cebpbflox/flox;Tie2cre (/) mice. Also in
this tumor model, tumor-infiltrating CD11b+ cells expressed
C/EBPb (LAP* isoform) that was lost in fully ablated mice
(Figure 4A, bottom panel). EG-7 tumor-bearing mice were adop-
tively transferred with OVA-specific CD8+ T cells from OT-1
mice, and after 7 days, lymph node cells were isolated and
restimulated ex vivo with either control or specific OVA peptide.
In Cebpbflox/+;Tie2cre (+/) tumor-bearing mice, reduced
numbers of OT-1 CD8+ T cells were recovered that poorly re-
sponded to stimulation with the specific peptide, as assessed
by IFN-g ELISPOT (Figure 4A, upper panel). This loss of
OVA-specific CD8+ T cell effectors was significantly overcome
in Cebpbflox/flox;Tie2cre (/) mice (p = 0.0016, Figure 4A), sug-
gesting that C/EBPb is a prominent regulator of tumor-induced
tolerance toward tumor-associated antigens.
To demonstrate further that absence of C/EBPb could revert
tumor-induced tolerance and provide therapeutic benefit, we
set up experiments of adoptive cell therapy of tumor-bearing
mice (Figure S4). To use a clinically relevant target, we trans-
ferred polyclonal CTLs recognizing the mouse telomerase
antigen (Mennuni et al., 2008; Ugel et al., 2010). Adoptive transfer
into wild-type mice bearing a subcutaneous MCA203 fibrosar-
coma was without effect on tumor growth, unless preceded by
myeloid and lymphoid ablation (Figure 4B), as reported for other
adoptive cell therapy protocols (Gattinoni et al., 2006; Ugel et al.,
2010). However, even in this case, therapeutic effectiveness was
limited, resulting in a short prolongation of mouse survival.
Whereas adoptive transfer of telomerase-specific CTLs did not
impact tumor progression in hemizygous Cebpbflox/+;Tie2cre
(+/) mice, significant prolongation of survival and complete
cure in more than 60% of mice was achieved in Cebpbflox/flox;
Tie2cre (/) tumor-bearing mice in the absence of any prior
ablation (Figure 4B). To our knowledge, this is one of the few
reports describing complete regression of established cancers
with polyclonal CTLs specific for tumor-associated self-
antigens.
Effect of C/EBPb Deficiency on Tumor Environment
Having established that the absence of C/EBPb affected the
number and tolerogenic activity of splenic MDSCs, we moved
Figure 3. C/EBPb Involvement in MDSC Suppressive Activity In Vitro
(A) Immunoblot for C/EBPb in CD11b+ cells isolated from spleens and tumors of mice bearing different tumors (upper panel) and fresh BM cells and BM cells
treated with GM-CSF+IL-6 for 12, 24, 48, 72, and 96 hr, isolated from either BALB/c or C57BL/6 mice (lower panels). Molecular weight of C/EBPb isoforms is
as follows: LAP* = 38 KD; LAP = 34 KD; LIP = 20 KD.
(B) In vitro suppressive activity of BM-derived MDSCs from C57BL/6, Cebpbflox/+;Tie2cre, and Cebpbflox/flox;Tie2cre mice was evaluated by adding increasing
numbers of BM-MDSCs to MLPC set up with gp100-specific CD8+ T lymphocytes from p-mel-1 transgenic mice. After 5 days, cytotoxic activity was tested in a
5 hr 51Cr-release assay. In vitro suppressive activity was evaluated, and data are expressed as the ratio between L.U.30 in MDSC-containing cultures and in
control cultures set up in the absence of MDSCs. Mean ± SD, n = 3 independent cultures/group; all comparisons are among MDSC containing cultures versus
cultures without MDSCs: *p% 0.05 and **p% 0.01, Student’s t test. BM-MDSCs were also evaluated in immunoblot for the expression of C/EBPb.
(C) Splenic accumulation of CD11b+Gr-1+ cells induced by MCA203 fibrosarcoma in C57BL/6 Cebpbflox/+;Tie2cre and Cebpbflox/flox;Tie2cre mice and suppres-
sive activity of CD11b+ splenocytes (mean ± SD of four independent experiments. **p % 0.01, Student’s t test, all comparisons are among MDSC containing
cultures versus cultures without MDSCs).
(D) CD11b+ cell subset accumulation in the spleen of C57BL/6 Cebpbflox/+;Tie2cre and Cebpbflox/flox;Tie2cre mice bearing MCA203 sarcomas. Mean ± SD
of three independent experiments (n = 6 mice in total. *p % 0.05 and **p % 0.01, Student’s t test. All comparisons are between Cebpbflox/+;Tie2cre and
Cebpbflox/flox;Tie2cre versus C57BL/6 mice).
See also Figure S3.
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the tumor microenvironment. Surprisingly, we did not observe
significant changes in growth rate of MCA203 and MN-MCA1
primary sarcomas (Figure 5A, left panel). We decided to usethe MN-MCA1 sarcoma since it spontaneously metastasizes to
lungs and several studies have shown that inflammation and
tumor-associated macrophages are responsible for the promo-
tion of malignancy in this tumor model (Saccani et al., 2006;Immunity 32, 790–802, June 25, 2010 ª2010 Elsevier Inc. 795
Figure 4. C/EBPb Involvement in Tumor-Induced Tolerance
(A) Cebpbflox/+;Tie2cre and Cebpbflox/flox;Tie2cremice were inoculated s.c with either PBS (no tumor) or with EG-7 tumor cells, and i.v. injected 7 days later with
OT-1 T cells. After an additional 7 days, mice were euthanized, lymph node cells stimulated with either OVA or b-gal peptides, and analyzed by IFN-g ELISPOT
assay. Data report the differences between the number of spots elicited by specific and control peptides per 106 cells. Mean ± SD, n = 6 mice/group pooled from
2 separate experiments (**p% 0.01); immunoblot analysis of spleen and tumor-infiltrating CD11b+ cells of Cebpbflox/+;Tie2cre and Cebpbflox/flox;Tie2cre EG-7
tumor-bearing mice.
(B) The suppressive influence of tumors in the absence of C/EBPb was tested in an adoptive immunotherapeutic setting in C57BL/6 Cebpbflox/+;Tie2cre and
Cebpbflox/flox;Tie2cre mice, as indicated in Figure S4 (n = 6 mice/group from two separate experiments; comparisons were performed with a Kaplan-Maier
log-rank test). Ablation by g-irradiation was performed only in a group of wild-type mice.
See also Figure S4.
Immunity
C/EBPb Controls Tumor-Induced ToleranceSica et al., 2000). In agreement with these findings, a sig-
nificant decrease in the number of pulmonary metastases in
Cebpbflox/flox;Tie2cremicewas observed (Figure 5A, right panel),
suggesting that C/EBPb might play a role in controlling tumor
spreading to distant sites.
When we analyzed CD11b+ cells infiltrating MCA203 tumors
grown in Cebpbflox/flox;Tie2cre mice, we detected significant
frequency changes among MDSCs only in the CD11b+Gr-1int
cell fraction (Figure 5B). We thus evaluated whether reduction
of this fraction, observed both in the spleen and tumor site of
in Cebpbflox/flox;Tie2cre mice, might be associated with
enhanced differentiation of other myeloid cells. In the spleens
of Cebpbflox/flox;Tie2cre mice, there was a significant decrease
of mature granulocytes associated with an increase in mono-
cytes-macrophages and DCs, a situation mirrored by the tumor
site with the only difference being that DCs infiltrating the tumor
were very few and their number was not affected by C/EBPb
deficiency (Figure 5C).
Despite the minor modifications in marker distribution among
tumor-associated CD11b+ cells in Cebpbflox/flox;Tie2cre mice,796 Immunity 32, 790–802, June 25, 2010 ª2010 Elsevier Inc.the ability of these cells to suppress, in a dose-depended
manner, the in vitro stimulation of CD8+ T cells was completely
abrogated compared to cells isolated from tumor grown in either
wild-type or hemizygous mice (Figure 5D).
The action of C/EBPb in the host response to cancer will
require further studies to unveil some intriguing aspects that
were not addressed because beyond the scope of this study.
The most important finding is certainly the metastasis promoting
activity of C/EBPb (Figure 5A). Moreover, while lack of C/EBPb
does not affect the ability of BM cells to proliferate in response
to GM-CSF+IL-6 cytokines (data not shown), it renders
CD11b+ cells originated from these cultures more prone to die
when cocultured with antigen-activated CD8+ T cells (Figures
S5A–S5C).
C/EBPb in Tumor-Infiltrating Myeloid Cells Controls
Enzymes with Negative Influence on T Cell Activation
We next evaluated whether C/EBPb might control the immu-
noregulatory pathways in MDSCs. Following separation of
CD11b+ cells from MCA203 tumor infiltrate, we found that loss
Figure 5. C/EBPb Controls Phenotype and Function
of Tumor-Infiltrating Myeloid Cells
(A) Left panel: tumor size indicated as whole area
(mean mm2 ± SD) was evaluated following s.c. inoculation of
the MCA203 fibrosarcoma in C57BL/6 Cebpbflox/+;Tie2cre
and Cebpbflox/flox;Tie2cre mice (n = 5 mice/group). Right
panel: number of lung metastases and weights of the primary
tumors assessed 28 days after i.m. inoculation of MN-MCA1
sarcoma cells in C57BL/6 and Cebpbflox/flox;Tie2cre mice
(n = 8 mice/group).
(B) CD11b+ cell subset accumulation at the tumor site in
C57BL/6 Cebpbflox/+;Tie2cre and Cebpbflox/flox;Tie2cre mice
bearing MCA203 tumors.
(C) Accumulation of different myeloid populations among
CD11b+ gated cells induced by MCA203 fibrosarcoma in
spleen and at tumor site of C57BL/6 Cebpbflox/+;Tie2cre and
Cebpbflox/flox;Tie2cre mice. Viable splenocytes were gated
as CD11b+F4/80+CD115+ monocytes, CD11b+F480+Gr-1
macrophages, CD11b+CD11c+IA-IE+ DCs, and CD11b+F4/
80Ly6G+ granulocytes. At the tumor site, viable cells were
gated in the same way, except for monocytes-macrophages,
which were overall considered as CD11b+ F4/80+ cells.
(D) In vitro suppressive activity of tumor-infiltrating
CD11b+ cells isolated from C57BL/6 Cebpbflox/+;Tie2cre and
Cebpbflox/flox;Tie2cre mice was evaluated by adding
increasing numbers of CD11b+ cells to MLPC set up with
gp100-specific CD8+ T lymphocytes from p-mel-1 transgenic
mice. After 5 days, cytotoxic activity was tested in a 5 hr
51Cr-release assay. In vitro suppressive activity was evalu-
ated, and data are expressed as the ratio between L.U.30 in
MDSC-containing cultures and in control cultures, set up in
the absence of MDSCs. Mean ± SD of three independent
experiments, all comparisons are among MDSC containing
cultures versus cultures without MDSCs: *p % 0.05, **p %
0.01, ***p% 0.001; Student’s t test.
See also Figure S5.
Immunity
C/EBPb Controls Tumor-Induced Toleranceof C/EBPb caused a significant reduction in both arginase 1
(Arg1) and nitric oxide synthase 2 (Nos2) proteins (Figure 6A),
two enzymes that were described as crucial components of
MDSC inhibitory machinery (Bronte and Zanovello, 2005; Gabri-
lovich and Nagaraj, 2009). Accordingly, enzyme activity was also
significantly reduced (Figure 6B). These results confirm and
extend an ample literature about the intervention of C/EBPb in
transcriptional control of either Nos2 or Arg1 genes (Gray
et al., 2005; Gupta and Kone, 1999; Pauleau et al., 2004; Teng
et al., 2002). It must be pointed out, however, that other genes,
such as Arg2, Nos isoforms different from Nos2 (i.e., Nos1 and
Nos3), or components of the phagocytic oxidase (Cyba and
Cybb), were described to contribute toMDSC’s ability to restrain
T lymphocyte activation and proliferation (Bronte et al., 2005;
Nagaraj et al., 2007). Interestingly, with the exception of
Arg2 that was not present in tumor-associated CD11b+ cell,
the mRNAs coding for all these enzymes were downregulated
in tumor-associated CD11b+ cells from Cebpbflox/flox;ImmunityTie2cre (/) tumor-bearing mice when compared
to hemyzygous Cebpbflox/+;Tie2cre (+/) mice
(Figure 6C), suggesting that lack of C/EBPb creates
a permissive intratumoral environment for T cell
proliferation.
Since Nos2 is pivotal in MDSC-induced suppres-
sion in C57BL/6 mice (Mazzoni et al., 2002; Serafiniet al., 2006), we compared the in vitro inhibitory activity of
CD11b+ splenocytes from tumor-bearing mice (spleen MDSCs)
and BM-MDSCs from either wild-type or Nos2 ablated mice.
Nos2 absence in both MDSC populations caused a substantial
loss of immunosuppressive activity on antigen-activated CD8+
T cells (Figure 6D), further confirming that these cells use similar
molecular mechanisms to restrain T cell activation.
Phenotype and Suppressive Activity of Human
BM-derived MDSCs
We recently demonstrated that, as is for mouse MDSCs, IL-4Ra
is a useful marker for human MDSC identification (Mandruzzato
et al., 2009). We therefore treated human BM cells in vitro with
GM-CSF, IL-6, and G-CSF, alone or in combination, and studied
their phenotype and functional activity. After 4 days, all cell
cultures showed a heterogeneous pattern of maturation ranging
from promyelocytes to mature granulocytes (Figure 7A and
Figure S6A), as indicated by the distribution of CD11b and32, 790–802, June 25, 2010 ª2010 Elsevier Inc. 797
Figure 6. C/EBPb Is a Major Regulator of
the Enzymes Involved in Lymphocyte Inhib-
itory Pathways Employed by Intratumoral
Myeloid Cells
(A) Immunoblot for C/EBPb, Arg1, and Nos2 in
CD11b+ cells isolated from the tumor mass of
wild-type C57BL/6 Cebpbflox/+;Tie2cre and
Cebpbflox/flox;Tie2cre MCA203-bearing mice;
histograms represent the mean ± SD of actin-
normalized, densitometric scans from three
different experiments; *p < 0.05, Student’s t test.
(B) CD11b+ cells were isolated from the tumor
mass of wild-type C57BL/6 Cebpbflox/+;Tie2cre
and Cebpbflox/flox;Tie2cre MCA203-bearing mice,
and Arg enzyme activity was evaluated immedi-
ately after cell isolation on cell extracts. CD11b+
cells were also plated, and supernatants were
collected 48 hr later and assayed for NO2
 and
NO3
 content to estimate Nos2 activity.
(C) Quantitative PCR evaluation of genes known to
be involved in MDSC-related immunosuppressive
pathways. Data are expressed on a base 2 loga-
rithmic scale as the fold change of mRNA abun-
dance in CD11b+ splenocytes isolated from
Cebpbflox/+;Tie2cre and Cebpbflox/flox;Tie2cre
MCA203-bearing mice, normalized to the expres-
sion of GAPDH housekeeping gene and compared
to abundance in wild-type C57BL/6 tumor-bearing
mice. Mean ± SD; n = 3 mice/group in one repre-
sentative experiment out of two.
(D) Suppressive activity exerted on MLPC by
either GM-CSF+IL-6-treated BM cells or CD11b+
cells isolated from the spleen of C57BL/6 and
Nos2/ MCA203 tumor-bearing mice was evalu-
ated by adding these cells as a third part to a
MLPC set up with gp100-specific CD8+ T cells.
Mean ± SD (**p% 0.01).
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C/EBPb Controls Tumor-Induced ToleranceCD16 myeloid markers (Elghetany et al., 2004; Stetler-Steven-
son et al., 2001). However, while G-CSF treatment induced a
marked maturation of CD16hiCD11b+ granulocytes, GM-CSF
treatment induced a population containing more immature cells
(Figure 7A), from myelocytes to band cells, that constituted
a continuum characterized by an increasing expression of
CD16 (Figure S6A). A combination of GM-CSF with either
G-CSF or IL-6 gave rise to a significant increase in more imma-
ture CD11b+CD16 elements (p% 0.01 compared to untreated
BM, n = 16, data not shown). Cytokines were able to upregulate
IL-4Ra expression, but a more pronounced effect was obtained
by G-CSF+GM-CSF combination (Figure 7B and Figure S6B).
Both cytokine combinations allowed us to recover about
70%–80% of the initial number of BM cells plated in culture
(Figure S2F, right panel).
To assess the functional activity of human BM-derived cell
cultures, we measured cell division by dilution of CFSE staining
in T cells stimulated with CD3+CD28 mAbs in the presence of798 Immunity 32, 790–802, June 25, 2010 ª2010 Elsevier Inc.BM-MDSCs. We observed a significant
inhibitory activity of GM-CSF+G-CSF
and GM-CSF+IL-6-derived human
MDSCs (Figure 7C, p % 0.05). In the
representative experiment shown in Fig-
ure 7D, addition of BM-MDSCs sup-pressed responder T cell proliferation, with an increase in the
percentage of cells in the parental generation and a parallel
decrease in the percentage of proliferating cells. Similar results
were obtained with alloantigen-stimulated peripheral blood
mononuclear cells (PBMCs, data not shown).
To assess the functional impact of decreased C/EBPb expres-
sion in the suppression of activated T lymphocytes mediated by
BM-MDSC, we knocked down transcription factor C/EBPb by
lentiviral-mediated transduction of shRNA. To this aim, we
expressed shRNA against C/EBPb in BM-MDSCs derived
from the combination of G-CSF+GM-CSF treatment. Real-time
RT-PCR and immunoblot analysis confirmed down-modulation
of C/EBPb transcripts and protein (Figure 7E). It must be pointed
out that molecular weights of human C/EBPb isoforms are
slightly different from mouse homologs, as previously reported
(Eaton et al., 2001). Three days after cytokine culture, shRNA-
treated BM-MDSCs were harvested, washed, and added to
CFSE-labeled PBMCs activated with anti-CD3+anti-CD28 and
Figure 7. Human MDSCs Can Be Induced
from BM Precursors by Growth Factor
Combinations
(A) BM cells were cultured in the presence of the
indicated cytokines for 4 days, and flow cytometry
was performed on cells gated inmyeloid region, as
identified by forward and side scatter. Left panels,
CD11b versus CD16 staining; right panels, CD15
versus IL-4Ra staining (one representative out of
three independent experiments).
(B) Percentage of IL-4Ra+CD15+ cells among BM
cultures stimulated with different cytokines (n = 4
independent experiments, on four BM samples
from four different individuals). *p % 0.05, **p %
0.01, ***p % 0.001, Student’s t test, all compari-
sons among cytokine-treated BM versus
untreated BM.
(C) Suppression of PBMCs activated with anti-
CD3 and anti-CD28 by human BM-MDSCs.
CFSE-labeled PBMCs were stimulated with
coated anti-CD3 and soluble anti-CD28 in the
presence of 1:1 ratio of either untreated BM cells
or BM cells cultured with different cytokines. After
four days, CFSE-labeled cells were harvested,
labeled with anti-CD3 and analyzed in the CD3+
gate. Quantification of proliferation was performed
by analyzing the number of proliferating cells from
generation 3 to generation 10, assumed to be
100% without BM-MDSCs. Mean ± SD, n = 12
BM samples, except n = 4 for GM-CSF+IL6;
*p% 0.05.
(D) Representative experiment (from samples
described in C) of cell division analysis in PBMCs
activated with anti-CD3 and anti-CD28 in the pres-
ence of human BM-MDSCs. Blue peaks on the
right indicate undivided cells (parent cells) and
each peak toward the left-hand side represents
one cell division or generation The percentages
of the undivided cells are shown.
(E) Reduction of C/EBPb was determined by
immunoblot (one representative out of three inde-
pendent experiments performed on three BM
samples from three individuals), and expression
was measured in duplicates by real-time RT-PCR;
mRNA decrease is displayed as a percentage rela-
tive to C/EBPb in cells transfected with control shRNA (mean ± SD, C/EBPb shRNA versus control shRNA, *p% 0.05, n = 3 independent experiments).
(F) shRNA knockdown of C/EBPb in BM-MDSCs restores T cell proliferation. BM cells were cultured o.n. with G-CSF and GM-CSF, then infected with control or
C/EBPb shRNA-encoding lentiviruses and kept 3 more days in culture with the cytokines. PBMCs were labeled with CFSE, activated with CD3+CD28 mAbs, and
cultured in the presence of BM-MDSCs (ratio PBMC:BM 1:1), either untreated or infected 3 days earlier with lentiviruses. After 4 days, cells were harvested and
stained with CD3 mAb (mean ± SD, n = 3 independent experiments with three BM samples from three individuals; *p% 0.05).
See also Figure S6.
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ure 7F, p = 0.026 BM-MDSC versus None) was reversed when
C/EBPb was silenced (p = 0.019 shC/EBPb BM-MDSC versus
control sh BM-MDSC), whereas no off-target effects were
observed with cells infected with lentiviruses encoding a control
shRNA (p = 0.133 control sh BM-MDSC versus BM-MDSC).
Our results show that, despite phenotypic differences among
mouse and human MDSCs, the immunoregulatory program in
these cells is controlled by the same transcription factor.
DISCUSSION
We show here that the tolerogenic and immunosuppressive
environment created by tumors critically depends on the tran-scription factor C/EBPb. The ablation of C/EBPb in the myeloid
compartment led to a reversal of tolerance in tumor-antigen
specific CD8+ T cells and revealed a full therapeutic activity of
tumor-specific CTLs on established tumors. This was associated
with a significant loss of the CD11b+ cell subset bearing low to
intermediate amounts of Gr-1 marker, a population likely
belonging to the monocytic differentiation lineage with immature
features and endowed with the greatest immunoregulatory
activity among the CD11b+ cells in tumor-bearing mice (Dolcetti
et al., 2010). Moreover, in tumor-bearing mice, C/EBPb ablation
increased the number of monocytes-macrophages and DCs
with a concomitant reduction in mature granulocytes, suggest-
ing that lack of C/EBPbmight lead also to an altered differentia-
tion of immature myeloid precursors. Our data identify a targetImmunity 32, 790–802, June 25, 2010 ª2010 Elsevier Inc. 799
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C/EBPb Controls Tumor-Induced Tolerancefor potential intervention aiming at reverting tumor-induced toler-
ance. Moreover, we also provided evidence indicating that
mouse and human MDSCs can be generated through a simple,
short-term culture system by a combination of cytokines that
are normally released under inflammatory conditions but are
also present in tumor microenvironment, further confirming the
link between MDSCs and inflammation (Cheng et al., 2008; Gal-
lina et al., 2006; Sica and Bronte, 2007).
All the cytokines we tested can signal through the transcription
factor C/EBPb (Hirai et al., 2006; Poli, 1998). CAAT-enhancer-
bindingproteins area family of leucine zipper transcription factors
involved in the regulation of various aspects of cellular differenti-
ation and controlling multiple functions related to inflammation
andmyeloid differentiation. Induction of C/EBPb by inflammatory
stimuli occurs inmost tissuesanalyzed, andexpression of various
C/EBP isoforms is differentially induced duringmacrophage and/
or granulocyte differentiation (Rosenbauer and Tenen, 2007).
However, whereas C/EBPa and 3 control myeloid differentiation
under steady-state conditions, C/EBPb is more important under
stress- and inflammatory-induced myelopoiesis (Hirai et al.,
2006). Our data thus hint to a more widespread role for this tran-
scription factor in dampening the consequences of prolonged
and heightened immune responses under different situations,
ranging from infectious diseases to trauma, a function that has
been ascribed to MDSCs (Bronte and Zanovello, 2005; Gabrilo-
vich and Nagaraj, 2009; Marigo et al., 2008).
Our resultsalsosupport theconcept thatMDSCsarenotpresent
under steady-state hematopoiesis but are instead released and
activated when alternative myelopoietic programs depending on
C/EBPb are elicited. In this regard, results with in vitro-generated
human MDSCs are quite relevant in light of differences existing
between mouse and human MDSCs and show that, despite
phenotypic diversity, a similar molecular program underlies the
immunoregulatory functions of myeloid cells. Human BM-MDSCs
derivedwithGM-CSF+G-CSFandGM-CSF+IL-6 lack fullymature
monocytes and granulocytes and consist of amixture of immature
cells, from monoblast and myeloblast to band cells, expressing
IL-4Ra chain.Weare currently investigatingwhether immunoregu-
latory properties of humanBM-MDSCs can be attributed to one or
more immature myelomonocytic subsets.
EXPERIMENTAL PROCEDURES
Mice
All mice were maintained under specific pathogen-free conditions in the
animal facilities of the Istituto Oncologico Veneto, and experiments were
performed according to state guidelines and approved by the local ethics
committee. Details of mice and cell culture are provided in Supplemental
Experimental Procedures.
Sample, Human Cohorts, and Treatments
Fresh BM aspirate samples with normal cytological characteristics were
obtained from patients with suspected leukemia or lymphomas, patients
with lymphatic leukemia after 78 days without recurrences, and patients with
lymphatic leukemia in post-BM transplantation (BMT) as a part of the diag-
nostic follow-up. Informed consent was obtained from all participating individ-
uals prior to the study, and the study was approved by the ethics committee.
Antibodies
The following Abs were used for flow cytometry analysis of mouse cells:
CD11b, Gr-1, CD124, CD62L CD11c, CD115, Ly6G, Ly6C, I-A-I-E, and800 Immunity 32, 790–802, June 25, 2010 ª2010 Elsevier Inc.IFN-g all from BD PharMingen; F4/80 from AbD Serotec; and CD45.2 and
CD90-Thy.1 from eBioscience. For staining of human cells, we used the
following antibodies: IgG2a and IL4Ra from R&D, Minneapolis; CD15,
CD11b, and CD16 from BD PharMingen; and human IgG from AbD Serotec.
Flow Cytometry Analysis
Quantitative flow cytometric analyses were performed using standard proce-
dures. Before staining with anti-mouse IFN-g, for analysis of intracellular
cytokine production, cells were incubated with Golgi stop for 10 hr, washed
and fixed, and then permeabilized for 20 min at 4C (Cytofix/Cytoperm Kit,
BD PharMingen) Data acquisition was performed using FACSCalibur flow
cytometer (Becton Dickinson) and analyzed by using FlowJo (Tree Star, Inc.).
CFSE Labeling and Proliferation Assay
PBMCs from healthy donor were stained with 0.5–1 mM carboxy-fluoroscein-
diacetate, succinimidyl ester (CFSE), according to manufacturer’s instructions
(Invitrogen Molecular Probe). CFSE-labeled PBMCs were stimulated with
coated 1 mg/ml anti-CD3 and 5 mg/ml soluble anti-CD28 for 4 days and cocul-
tured at 1:1 ratio with BM-MDSCs in 96 flat bottom well plates. After 4 days,
cells were stained with CD3 (Immunotools, Germany), and CFSE signal of
gated lymphocytes was analyzed. The extent of cell proliferation was quanti-
fied by ModFit LT software V3.0 (Verity Software House, Inc.).
ELISA and ELISPOT Assay
ELISA for mouse GM-CSF (Endogen), IL-6 (eBioscience), G-CSF (Biosource),
and IFN-g release (Endogen) release was performed according to manufac-
turer’s instructions. The number of IFN-g spots in response to the stimulation
with specific or control peptides (1 mg/ml) was evaluated with the mouse IFN-g
ELISPOT Kit (BD PharMingen), following manufacturer’s instructions. Each
well contained 5 3 105 lymph node cells. The number of spots was evaluated
in triplicates by using an automated ELISPOT reader (Eli.scan, A.EL.VIS
GmbH, Germany).
Adoptive Cell Therapy
Adoptive cell therapy (ACT) was performed inmice after s.c. challengewith 13
106 MCA203 cells as described in Mennuni et al. (2008) and Ugel et al. (2010)
and in Figure S4.
Diabetes Induction
BALB/c recipient mice were administered Streptozotocin (STZ, 150 mg/kg,
i.p.) (Sigma-Aldrich Inc., MO, USA) to induce diabetes. STZ solution was
prepared in freshly prepared pH 4.6 citrate buffer. Glycemia was monitored
every 1 to 2 days prior to transplant (using an Accu-Chek Avviva glucometer,
Roche Diagnostics, Mannheim, Germany), and diabetes was confirmed
following two consecutive blood glucose measurements > 250 mg/dl.
Islet Transplantation
Islets were transplanted under the left kidney capsule of STZ-induced diabetic
recipient mice as previously described by Machen et al. (2004). Antibiotics
were administered immediately after and every 3 to 4 days following surgery
for the duration of the MDSC-treatment regimen. Graft rejection was defined
by two consecutive blood glucose measurements > 250 mg/dl following a
period of stable normoglycaemia.
Total RNA Purification and Real-Time PCR Analysis
Total RNA extraction and real-time analysis were performed as previously
described (Gallina et al., 2006).
Statistics
Unless otherwise stated, all the experiments were repeated three times.
Survival experiments were represented with Kaplan-Meier curve, and
significance was estimated with the log-rank test. The nonparametric one-
tailed exact Wilcoxon signed-rank test and two-tailed exact Wilcoxon test
for paired samples were used for human data analysis (when specified).
Student’s t test was used to compare parametric groups. Values were consid-
ered statistically significant at p < 0.05. Absence of significance was not
reported for brevity.
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An expanded version of this section is provided in Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at doi:10.1016/j.
immuni.2010.05.010.
ACKNOWLEDGMENTS
We thank Dr. A. Corradin for support in statistical analysis and E. Peranzoni
and S. Zilio for help with cytofluorimetric studies. This work was supported
by grants from the Italian Ministry of Health, Fondazione Cassa di Risparmio
di Padova e Rovigo, Italian Association for Cancer Research (AIRC), project
RSF/2005/R/5 from Fondazione Italiana Sclerosi Multipla (FISM), Association
for International Cancer Research (AICR, Grant 08-0518), and Istituto Superi-
ore Sanita` -Alleanza Contro il Cancro (project no. ACC8).
Received: January 4, 2010
Revised: March 17, 2010
Accepted: May 20, 2010
Published online: June 3, 2010
REFERENCES
Bronte, V., and Zanovello, P. (2005). Regulation of immune responses by
L-arginine metabolism. Nat. Rev. Immunol. 5, 641–654.
Bronte, V., Chappell, D.B., Apolloni, E., Cabrelle, A., Wang, M., Hwu, P., and
Restifo, N.P. (1999). Unopposed production of granulocyte-macrophage
colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysre-
gulating antigen-presenting cell maturation. J. Immunol. 162, 5728–5737.
Bronte, V., Apolloni, E., Cabrelle, A., Ronca, R., Serafini, P., Zamboni, P.,
Restifo, N.P., and Zanovello, P. (2000). Identification of a CD11b(+)/Gr-1(+)/
CD31(+) myeloid progenitor capable of activating or suppressing CD8(+)
T cells. Blood 96, 3838–3846.
Bronte, V., Kasic, T., Gri, G., Gallana, K., Borsellino, G., Marigo, I., Battistini, L.,
Iafrate, M., Prayer-Galetti, T., Pagano, F., and Viola, A. (2005). Boosting anti-
tumor responses of T lymphocytes infiltrating human prostate cancers. J.
Exp. Med. 201, 1257–1268.
Cheng, P., Corzo, C.A., Luetteke, N., Yu, B., Nagaraj, S., Bui, M.M., Ortiz, M.,
Nacken, W., Sorg, C., Vogl, T., et al. (2008). Inhibition of dendritic cell differen-
tiation and accumulation of myeloid-derived suppressor cells in cancer is
regulated by S100A9 protein. J. Exp. Med. 205, 2235–2249.
Dolcetti, L., Peranzoni, E., Ugel, S., Marigo, I., Fernandez Gomez, A., Mesa, C.,
Geilich, M., Winkels, G., Traggiai, E., Casati, A., et al. (2010). Hierarchy of
immunosuppressive strength amongmyeloid-derived suppressor cell subsets
is determined by GM-CSF. Eur. J. Immunol. 40, 22–35.
Eaton, E.M., Hanlon, M., Bundy, L., and Sealy, L. (2001). Characterization of
C/EBPbeta isoforms in normal versus neoplastic mammary epithelial cells.
J. Cell. Physiol. 189, 91–105.
El Kasmi, K.C., Qualls, J.E., Pesce, J.T., Smith, A.M., Thompson, R.W.,
Henao-Tamayo, M., Basaraba, R.J., Ko¨nig, T., Schleicher, U., Koo, M.S., et al.
(2008). Toll-like receptor-induced arginase 1 in macrophages thwarts effective
immunity against intracellular pathogens. Nat. Immunol. 9, 1399–1406.
Elghetany, M.T., Ge, Y., Patel, J., Martinez, J., and Uhrova, H. (2004). Flow
cytometric study of neutrophilic granulopoiesis in normal bone marrow using
an expanded panel of antibodies: correlation with morphologic assessments.
J. Clin. Lab. Anal. 18, 36–41.
Gabrilovich, D.I., and Nagaraj, S. (2009). Myeloid-derived suppressor cells as
regulators of the immune system. Nat. Rev. Immunol. 9, 162–174.
Gallina, G., Dolcetti, L., Serafini, P., De Santo, C., Marigo, I., Colombo, M.P.,
Basso, G., Brombacher, F., Borrello, I., Zanovello, P., et al. (2006). Tumors
induce a subset of inflammatory monocytes with immunosuppressive activity
on CD8+ T cells. J. Clin. Invest. 116, 2777–2790.Gattinoni, L., Powell, D.J., Jr., Rosenberg, S.A., and Restifo, N.P. (2006).
Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol.
6, 383–393.
Gray, M.J., Poljakovic, M., Kepka-Lenhart, D., and Morris, S.M., Jr. (2005).
Induction of arginase I transcription by IL-4 requires a composite DNA
response element for STAT6 and C/EBPbeta. Gene 353, 98–106.
Gupta, A.K., and Kone, B.C. (1999). CCAAT/enhancer binding protein-beta
trans-activates murine nitric oxide synthase 2 gene in an MTAL cell line. Am.
J. Physiol. 276, F599–F605.
Hirai, H., Zhang, P., Dayaram, T., Hetherington, C.J., Mizuno, S., Imanishi, J.,
Akashi, K., and Tenen, D.G. (2006). C/EBPbeta is required for ‘emergency’
granulopoiesis. Nat. Immunol. 7, 732–739.
Machen, J., Bertera, S., Chang, Y., Bottino, R., Balamurugan, A.N., Robbins,
P.D., Trucco, M., and Giannoukakis, N. (2004). Prolongation of islet allograft
survival following ex vivo transduction with adenovirus encoding a soluble
type 1 TNF receptor-Ig fusion decoy. Gene Ther. 11, 1506–1514.
Mandruzzato, S., Solito, S., Falisi, E., Francescato, S., Chiarion-Sileni, V.,
Mocellin, S., Zanon, A., Rossi, C.R., Nitti, D., Bronte, V., and Zanovello, P.
(2009). IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer
patients. J. Immunol. 182, 6562–6568.
Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P., and Bronte, V. (2008).
Tumor-induced tolerance and immune suppression by myeloid derived
suppressor cells. Immunol. Rev. 222, 162–179.
Mazzoni, A., Bronte, V., Visintin, A., Spitzer, J.H., Apolloni, E., Serafini, P.,
Zanovello, P., and Segal, D.M. (2002). Myeloid suppressor lines inhibit T cell
responses by an NO-dependent mechanism. J. Immunol. 168, 689–695.
Mennuni, C., Ugel, S., Mori, F., Cipriani, B., Iezzi, M., Pannellini, T., Lazzaro, D.,
Ciliberto, G., La Monica, N., Zanovello, P., et al. (2008). Preventive vaccination
with telomerase controls tumor growth in genetically engineered and carcin-
ogen-induced mouse models of cancer. Cancer Res. 68, 9865–9874.
Nagaraj, S., Gupta, K., Pisarev, V., Kinarsky, L., Sherman, S., Kang, L., Herber,
D.L., Schneck, J., and Gabrilovich, D.I. (2007). Altered recognition of antigen is
a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13, 828–835.
Pauleau, A.L., Rutschman, R., Lang, R., Pernis, A., Watowich, S.S., and
Murray, P.J. (2004). Enhancer-mediated control of macrophage-specific
arginase I expression. J. Immunol. 172, 7565–7573.
Poli, V. (1998). The role of C/EBP isoforms in the control of inflammatory and
native immunity functions. J. Biol. Chem. 273, 29279–29282.
Qiu, X., Aiken, K.J., Chokas, A.L., Beachy, D.E., and Nick, H.S. (2008). Distinct
functions of CCAAT enhancer-binding protein isoforms in the regulation of
manganese superoxide dismutase during interleukin-1beta stimulation. J.
Biol. Chem. 283, 25774–25785.
Rosenbauer, F., and Tenen, D.G. (2007). Transcription factors in myeloid
development: balancing differentiation with transformation. Nat. Rev. Immu-
nol. 7, 105–117.
Saccani,A.,Schioppa,T.,Porta,C.,Biswas,S.K.,Nebuloni,M.,Vago,L.,Bottazzi,
B., Colombo,M.P.,Mantovani, A., andSica,A. (2006). p50nuclear factor-kappaB
overexpression in tumor-associated macrophages inhibits M1 inflammatory
responses and antitumor resistance. Cancer Res. 66, 11432–11440.
Serafini, P., Carbley, R., Noonan, K.A., Tan, G., Bronte, V., and Borrello, I.
(2004). High-dose granulocyte-macrophage colony-stimulating factor-
producing vaccines impair the immune response through the recruitment of
myeloid suppressor cells. Cancer Res. 64, 6337–6343.
Serafini, P., Meckel, K., Kelso, M., Noonan, K., Califano, J., Koch, W., Dolcetti,
L., Bronte, V., and Borrello, I. (2006). Phosphodiesterase-5 inhibition augments
endogenous antitumor immunity by reducing myeloid-derived suppressor cell
function. J. Exp. Med. 203, 2691–2702.
Serafini, P., Mgebroff, S., Noonan, K., and Borrello, I. (2008). Myeloid-derived
suppressor cells promote cross-tolerance in B-cell lymphoma by expanding
regulatory T cells. Cancer Res. 68, 5439–5449.
Sica, A., and Bronte, V. (2007). Altered macrophage differentiation and
immune dysfunction in tumor development. J. Clin. Invest. 117, 1155–1166.
Sica, A., Saccani, A., Bottazzi, B., Polentarutti, N., Vecchi, A., van Damme, J.,
and Mantovani, A. (2000). Autocrine production of IL-10 mediates defectiveImmunity 32, 790–802, June 25, 2010 ª2010 Elsevier Inc. 801
Immunity
C/EBPb Controls Tumor-Induced ToleranceIL-12 production and NF-kappa B activation in tumor-associated macro-
phages. J. Immunol. 164, 762–767.
Stetler-Stevenson, M., Arthur, D.C., Jabbour, N., Xie, X.Y., Molldrem, J.,
Barrett, A.J., Venzon, D., and Rick, M.E. (2001). Diagnostic utility of flow cyto-
metric immunophenotyping in myelodysplastic syndrome. Blood 98, 979–987.
Teng, X., Li, D., Catravas, J.D., and Johns, R.A. (2002). C/EBP-beta mediates
iNOS induction by hypoxia in rat pulmonary microvascular smooth muscle
cells. Circ. Res. 90, 125–127.802 Immunity 32, 790–802, June 25, 2010 ª2010 Elsevier Inc.Ugel, S., Scarselli, E., Iezzi, M., Mennuni, C., Pannellini, T., Calvaruso, F.,
Cipriani, B., De Palma, R., Ricci-Vitiani, L., Peranzoni, E., et al. (2010).
Autoimmune B cell lymphopenia following successful adoptive therapy with
telomerase-specific T lymphocytes. Blood 115, 1374–1384. Published online
November 10, 2009. 10.1182/blood-2009-07-233270.
Youn, J.I., Nagaraj, S., Collazo, M., and Gabrilovich, D.I. (2008). Subsets of
myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181,
5791–5802.
